Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster represented RA Capital and OrbiMed as lead investors in Janux Therapeutics’ $125 million Series B financing. OrbiMed and RA Capital are two of the world’s leading healthcare venture capital firms. Janux Therapeutics is developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. RA Capital and OrbiMed were joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company) and Janux’s existing investors, Avalon Ventures, and Bregua.

MoFo Advises RA Capital/OrbiMed on $125M Series B Financing

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster represented RA Capital and OrbiMed as lead investors in Janux Therapeutics’ $125 million Series B financing. OrbiMed and RA Capital are two of the world’s leading healthcare venture capital firms. Janux Therapeutics is developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. RA Capital and OrbiMed were joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company) and Janux’s existing investors, Avalon Ventures, and Bregua.MoFo previously represented RA Capital and OrbiMed in Janux’s $56 million Series A financing which closed in March 2021.The MoFo team was led by San Diego corporate attorneys Jim Krenn, Brennen Brodersen, Andrew Dixon and Carey Hughes.<a href="https://www.januxrx.com/janux-therapeutics-closes-125-million-series-b-financing-to-advance-next-generation-t-cell-engager-immunotherapies-into-clinical-trials/" target="_blank">Further information regarding the financing</a>.

MoFo Advises RA Capital/OrbiMed on $125M Series B Financing

Sign Up

Jim Krenn

Partner

Andrew P Dixon

Associate

Carey Hughes

Emerging Companies + Venture Capital